查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1553475

骨髓發育不良症候群藥物市場規模、佔有率和趨勢分析報告：2024-2030 年按治療、給藥途徑、最終用途、地區和細分市場進行的預測

Myelodysplastic Syndrome Drugs Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Immune Treatments), By Route Of Administration, By End-use (Hospitals, Clinics), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

骨髓發育不良症候群藥物市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，2030年全球骨髓發育不良症候群藥物市場規模預計將達到52.8億美元，2024年至2030年複合年成長率為9.1%。

強大的產品平臺、不斷增加的老年人口以及有利的政府措施等因素正在推動市場發展。

MDS 是由控制血球發育的一個或多個基因突變引起的。患有這種疾病的患者表現出血小板減少、嗜中性白血球低下和貧血等臨床症狀。儘管大多數病例（超過 90%）發生在 60 歲以上的人群中，但這種疾病可以發生在任何年齡，並且男性比女性更常見。約 30% 的 MDS 病例會進展為急性骨髓性白血病(AML)。

由於來那Revlimid)的強勁銷售，免疫調節劑領域預計將保持其在 MDS 治療市場的主導地位。在 Luspatercept 和 Aranesp 可能核准的推動下，惡性物領域預計將比低甲基化藥物獲得更高的市場佔有率，並對整體市場擴張做出重大貢獻。

由於MDS在分子層面上是一種高度異質性的疾病，因此開發治療罕見患者亞群的新藥是一個重要的挑戰。此外，由於標準治療模式無效而導致的發病問題和生活品質下降也給老年人帶來不便。

骨髓發育不良症候群藥物市場報告亮點

  • 幹細胞移植將主導市場，2023年將佔38.7%的佔有率。幹細胞移植使用健康捐贈者的幹細胞來取代受損的骨髓。幹細胞移植可以恢復因高劑量化療或放射線治療受損的骨髓。
  • 2023年，口服給藥途徑佔最大的市場收益佔有率，達59.5%。口服藥物的優勢，例如消除與錠劑和注射相關的不利事件，是推動市場成長的一些因素。
  • 2023 年，醫院產業佔據最大的市場收益佔有率，達到 48.6%。慢性病盛行率的上升促使醫院提供無法家用治療的加護治療。
  • 2023年北美骨髓發育不良症候群藥物市場收益佔有率佔比為35.44%。這一成長是由老年人口的增加和骨髓發育不良症候群（MDS）的增加所推動的。
  • 據估計，亞太地區骨髓發育不良症候群藥物市場在預測期內複合年成長率最快。這一成長背後的主要因素是人口老化的加劇以及企業和研究機構的進步。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章骨髓發育不良症候群藥物市場變數、趨勢、範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 骨髓發育不良症候群藥物市場分析工具
    • 波特的分析
    • PESTEL分析

第4章骨髓發育不良症候群藥物市場：依治療方法估算與趨勢分析

  • 細分儀表板
  • 骨髓發育不良症候群藥物市場：2023 年和 2030 年治療的變異分析
  • 化療
  • 免疫療法
  • 幹細胞移植
  • 其他治療類型

第5章骨髓發育不良症候群藥物市場：按應用估計和趨勢分析

  • 細分儀表板
  • 骨髓發育不良症候群藥物市場：2023 年及 2030 年給藥途徑變異分析
  • 口服
  • 胃腸外的

第6章骨髓發育不良症候群藥物市場：最終用途的估計和趨勢分析

  • 細分儀表板
  • 骨髓發育不良症候群藥物市場：2023 年和 2030 年最終用途變異分析
  • 醫院
  • 診所
  • 其他

第7章骨髓發育不良症候群藥物市場：區域估計和趨勢分析

  • 2023 年及 2030 年骨髓發育不良症候群藥物市場佔有率（按地區）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
  • 拉丁美洲
    • 巴西
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第8章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • Celgene Corporation
    • Otsuka Pharmaceutical Co. Ltd
    • Amgen Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Sun Pharmaceutical Industries Limited
    • Takeda Pharmaceutical Company Ltd
    • Mylan NV
    • Cipla Pharmaceutical Limited
    • Onconova Therapeutics
    • Hikma Pharmaceuticals PLC
簡介目錄
Product Code: GVR-2-68038-434-5

Myelodysplastic Syndrome Drugs Market Growth & Trends:

The global myelodysplastic syndrome drugs market size is expected to reach USD 5.28 billion by 2030, exhibiting at a CAGR of 9.1% from 2024 to 2030, according to a new report by Grand View Research, Inc. Factors such as strong product pipeline, rising geriatric population, and favorable government initiatives are driving the market.

MDS is caused by mutation of one or more genes that control development of blood cells. Patients with this condition may present with clinical manifestations such as thrombocytopenia, neutropenia, and anemia. Although majority of cases (over 90%) are reported in people over the age of 60, the condition can occur at any age, more frequently in men than in women. About 30% of MDS cases advance to acute myeloid leukemia (AML).

The immunomodulatory drug segment is expected to retain its dominant position in the MDS drugs market due to strong sales of Revlimid. Supported by potential approvals of luspatercept and Aranesp, the anti-anemics drug segment is forecast to gain higher market share than hypomethylating agents, thus contributing significantly to the overall expansion of the market.

Developing novel drugs for the treatment of rare subsets of MDS patients is a key challenge as the disease is highly heterogeneous at the molecular level. In addition, morbidity issues and poor quality of life due to incapacitating effects of the standard of care treatment paradigms are causes of inconvenience for geriatric population.

Myelodysplastic Syndrome Drugs Market Report Highlights:

  • Stem cell transplant dominated the market and accounted for a share of 38.7% in 2023. Stem transplants use stem cells from healthy donors to replace damaged bone marrow. Stem cell transplant has the potential to restore the bone marrow damaged from high chemotherapy doses or from radiation therapy.
  • Oral route of administration accounted for the largest market revenue share of 59.5% in 2023. The advantages of oral medicines, such as tablets and the elimination of injection-associated adverse events, are a few factors driving the market growth.
  • The hospital segment accounted for the largest market revenue share of 48.6% in 2023. The rising prevalence of chronic diseases is driving hospitals to provide a concentrated treatment that cannot be treated at home.
  • North America's myelodysplastic syndromes drugs market dominated with revenue share of 35.44% in 2023. This growth is attributed to the growing geriatric population and growing incidences of myelodysplastic syndrome (MDS).
  • The Asia Pacific myelodysplastic syndrome drugs market is estimated to register the fastest CAGR over the forecast period. The growth is primarily attributed to the rising geriatric population and advancements by companies and research institutions.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Myelodysplastic Syndrome Drugs Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Myelodysplastic Syndrome Drugs Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Myelodysplastic Syndrome Drugs Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Myelodysplastic Syndrome Drugs Market: Product Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Chemotherapy
    • 4.3.1. Chemotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Immune Treatments
    • 4.4.1. Immune Treatments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Stem Cell Transplant
    • 4.5.1. Stem Cell Transplant Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Other Treatment Types
    • 4.6.1. Other Treatment Types Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Myelodysplastic Syndrome Drugs Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Myelodysplastic Syndrome Drugs Market: Route of Administration Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Oral
    • 5.3.1. Oral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Parenteral
    • 5.4.1. Parenteral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Myelodysplastic Syndrome Drugs Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Myelodysplastic Syndrome Drugs Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Hospitals
    • 6.3.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Clinics
    • 6.4.1. Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Other
    • 6.5.1. Other Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Myelodysplastic Syndrome Drugs Market: Regional Estimates & Trend Analysis

  • 7.1. Myelodysplastic Syndrome Drugs Market Share, By Region, 2023 & 2030 (USD Million)
  • 7.2. North America
    • 7.2.1. North America Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. China Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Japan
      • 7.4.3.1. Japan Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Saudi Arabia Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. UAE
      • 7.6.3.1. UAE Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. South Africa
      • 7.6.4.1. South Africa Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Celgene Corporation
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Otsuka Pharmaceutical Co. Ltd
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Amgen Inc.
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Teva Pharmaceutical Industries Ltd.
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Sun Pharmaceutical Industries Limited
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Takeda Pharmaceutical Company Ltd
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Mylan N.V.
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Cipla Pharmaceutical Limited
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. Onconova Therapeutics
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Hikma Pharmaceuticals PLC
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives